StemSys® was created to advance healing technologies and tissue regeneration in a variety of therapeutic applications. The multi-tissue platform (MTP) was developed to overcome the limitations of previous tissue derived products. With over 20 years of experience working in the field of tissue regeneration, StemSys is committed to developing novel medical devices that help restore the function of diseased or damaged tissue and help even the most severely injured heal.
StemSys provides innovative solutions to address unmet needs in current medical technology. The company is committed to the development of high quality, safe, and cost-effective solutions that significantly improve patient outcomes.
The multi-tissue platform (MTP) was developed to combine multiple ECM materials in varying ratios to allow for customization of desired components in the final biomaterial device and facilitate site specific healing and tissue regeneration. There are an almost endless number of possible combinations of ECMs that can be designed for site specific defects and applications. Each ECM material is composed of a unique combination of several components, such as:
PROTEINS AND GLYCOSAMINOGLYCANS (GAGS):
FIBROBLAST GROWTH FACTOR (FGF)
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
EPIDERMAL GROWTH FACTOR (EGF)
PLATELET DERIVED GROWTH FACTOR (PDGF)
XCelliStem® Wound Powder
XCelliStem Wound Powder is a proprietary blend utilizing multiple extracellular matrix materials derived from the multi-tissue platform (MTP). Rather than one single biomolecule, a number of different components work together to facilitate healing and repair. The proprietary technology platform can provide a custom blend of these components for advanced wound healing applications. StemSys combines multiple ECM materials in varying ratios to allow for customization of desired components in the final biomaterial device and facilitates site specific healing and tissue regeneration.